VistaGen Therapeutics (NASDAQ:VTGN) Share Price Passes Below Fifty Day Moving Average – Here’s What Happened

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.25 and traded as low as $0.24. VistaGen Therapeutics shares last traded at $0.2434, with a volume of 319,344 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a research note on Monday, August 31st. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Trading Up 1.5%

The stock’s 50-day moving average price is $0.25 and its 200-day moving average price is $0.47. The company has a market cap of $10.61 million, a P/E ratio of -0.14 and a beta of 0.39.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.The firm had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. On average, research analysts anticipate that VistaGen Therapeutics, Inc. will post -1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new position in VistaGen Therapeutics during the first quarter worth about $25,000. Schonfeld Strategic Advisors LLC bought a new position in VistaGen Therapeutics during the third quarter worth about $39,000. Millennium Management LLC bought a new position in VistaGen Therapeutics in the 3rd quarter worth approximately $73,000. Bank of America Corp DE boosted its holdings in shares of VistaGen Therapeutics by 1,068.0% in the fourth quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares during the period. Finally, Marshall Wace LLP bought a new position in VistaGen Therapeutics in the 2nd quarter worth about $69,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.